Bioqual, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOQ research report →
Companywww.bioqual.com
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer.
- CEO
- Hanne Andersen-Elyard
- IPO
- 2002
- Employees
- 278
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $31.31M
- P/E
- -25.33
- P/S
- 0.74
- P/B
- 0.89
- EV/EBITDA
- 39.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -6.99%
- Op Margin
- -5.40%
- Net Margin
- -2.92%
- ROE
- -3.46%
- ROIC
- -2.67%
Growth & Income
- Revenue
- $48.87M · -16.60%
- Net Income
- $-1,048,154 · -316.79%
- EPS
- $-1.17 · -316.67%
- Op Income
- $-1,896,010
- FCF YoY
- -69.12%
Performance & Tape
- 52W High
- $45.00
- 52W Low
- $33.00
- 50D MA
- $37.09
- 200D MA
- $38.93
- Beta
- -0.06
- Avg Volume
- 4
Get TickerSpark's AI analysis on BIOQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 11 | WILLIAMS FRANK E JR | other | 0 |
Our BIOQ Coverage
We haven't published any research on BIOQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOQ Report →